AI-Driven Early Detection of Skin Cancer

Nuvana Healthcare LTD

Status: Begins enrollment this month

Conditions: Skin Cancer Melanoma

Treatments: Diagnostic Test: Smartphone-based AI skin lesion analysis (NuvanaDx platform).

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT07144306

70148

359904 (Other Identifier)

Details and patient eligibility

About

This study evaluates the feasibility and accuracy of an AI-powered mobile platform (NuvanaDx) for early detection of skin cancer, including melanoma, using smartphone-based imaging. The platform is designed to improve access to early diagnosis, reduce waiting times, and support triage into appropriate care pathways.

Full description

The study will collect retrospective and prospective anonymized skin lesion images and metadata to validate the AI algorithm against dermatology-confirmed diagnoses. The aim is to determine sensitivity, specificity, and predictive value of the AI tool across diverse populations and skin tones. The study will also assess user experience, accessibility, and integration into clinical care pathways.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ months old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Adults (≥18 years) presenting with skin lesions suspicious for malignancy.

Ability to provide informed consent.

Exclusion criteria

Inability to provide informed consent.

Poor-quality images unsuitable for AI analysis.

Trial design

100 participants in 1 patient group

Participants with suspicious skin lesions undergoing AI-based image analysis and dermatologist confi

Treatment:

Diagnostic Test: Smartphone-based AI skin lesion analysis (NuvanaDx platform).